St. Jude Medical Announces Commencement of Public Offering of Senior Debt

St. Jude Medical, Inc. (NYSE:STJ) today announced it is commencing an offering of senior debt securities, subject to market and other customary conditions. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of certain of its indebtedness and the repurchase of its outstanding common stock pursuant to its authorized $500 million share repurchase program, as separately announced.

BofA Merrill Lynch is acting as active booking-running manager for the offering. A shelf registration statement relating to the offering was filed with the U.S. Securities and Exchange Commission on July 22, 2009. The offering will be made pursuant to a prospectus supplement to the Company�s prospectus, dated July 22, 2009, filed as part of the Company�s effective shelf registration statement relating to these securities.

Copies of the preliminary prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting BofA Merrill Lynch, 100 West 33rd Street, New York, New York 10001, Attention: Prospectus Department.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 15,000 people worldwide and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.

Forward-Looking Statements

Statements made in this news release may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including with regard to the Company's planned offering and the anticipated use of the net proceeds. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "expect," "estimate," "should," and similar expressions. Such forward-looking statements are inherently subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. No assurance can be given that the offering will be consummated on the terms described above or at all. Consummation of the offering and the terms thereof are subject to numerous conditions, risks and uncertainties which include market conditions, other factors beyond the Company�s control and the risk factors and other cautionary statements described in the Company�s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company�s Quarterly Report on Form 10-Q for the fiscal quarter ended April 4, 2009. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024